Arrakis Therapeutics is pioneering a new class of genetic medicines known as RNA-targeted small molecules (rSMs), aiming to unlock new biology for patients by creating oral medicines that target RNA
Arrakis Therapeutics is pioneering a new class of genetic medicines known as RNA-targeted small molecules (rSMs), aiming to unlock new biology for patients by creating oral medicines that target RNA.
Arrakis Therapeutics is pioneering a new class of genetic medicines known as RNA-targeted small molecules (rSMs), aiming to unlock new biology for patients by creating oral medicines that target RNA
Arrakis Therapeutics is pioneering a new class of genetic medicines known as RNA-targeted small molecules (rSMs), aiming to unlock new biology for patients by creating oral medicines that target RNA.